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Abstract: Aim. To investigate whether the nitric oxide (NO)/cyclic GMP (cGMP) signalling pathway, in 
basal conditions and stimulated by sodium nitroprusside (SNP), may disclose abnormal patterns in 
platelets from patients with an acute coronary syndrome.   
Design. Platelet activation (sP-selectin), inflammation (TNF-α and erythrosedimentation rate), 
thrombotic state (fibrinogen) and plaque disruption (HsCRP) markers were assessed in ten patients  
with unstable angina (UA), 14 with acute myocardial infarction (AMI) and 14 age and sex macthed 
healthy subjects. Platelets homogenates western blot analysis were performed, in basal conditions and 
stimulated by SNP, to assess cGMP levels and the expression of the sGC isoforms. Upstream (Akt1 
protein kinase α phosphorylation at Ser473 and eNOS phosphorylation) and downstream (vasodilator- 
stimulated phosphoprotein phosphorylation) signalling of the NO/cGMP pathway was tested in the 
three study groups.  
Results. Platelet activation, inflammation, thrombotic state and plaque disruption markers proved 
significantly higher in both the UA and AMI patients compared to healthy controls. Basal levels of cGMP 
(pmol/1010 platelets) were higher in platelets from UA (1097±111, p<0.0001) and AMI (1122±77, 
p<0.0001) patients compared to those from healthy controls (497±80). Similarly, serine 
phosphorylation in several proteins of the NO/cGMP signalling pathway (Akt1 protein kinase, NO  
synthase and VASP) was more represented in platelets from UA and AMI patients compared to controls.  
Following SNP stimulation AMI platelets disclosed a lack of cGMP increase and of VASP 
phosphorilation in comparison with healthy controls.  
Conclusion. The present study supports the hypothesis that low concentrations of endogenously  
synthesized NO and cGMP may promote platelet activation. The increased inflammatory state which  
often accompanies an acute coronary syndrome may be responsible of the platelet activation via the 
NO/cGMP pathway. Furthermore, platelets from AMI patients seem more resistant to SNP stimulation, 
exerted not only at the cGMP level but also at other signalling check-points.  
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Nitric  oxide (NO)  is an  important modulator of  both vasomotor tone and platelet function, 
 
leading to vasodilation and inhibition of platelet aggregation and adhesion [27]. NO induces  
 
these effects by stimulating soluble guanilate cyclase (sGC): the subsequent increase of cyclic  
 
guanosine  3',5'-monophosphate (cGMP) synthesis  modulates several effectors, such as  
 
cGMP-dependent protein kinase (PKG), cGMP-dependent ion channels and cGMP-regulated  
 
phosphodiesterases [24]. Chronic as well  as acute symptomatic coronary  heart disease  has 
 
been associated with increased platelet aggregability and NO resistance, detected as decreased  
 
platelet responsiveness to the antiaggregatory effects of NO donors, such as nitroglycerin and  
 
sodium nitroprusside  (SNP) [4]. Previous  work from our group has suggested that unstable  
 
angina (UA) and acute myocardial infarction (AMI) are conditions associated with increased  
 
platelet aggregability and NO resistance, measured as decreased platelet responsiveness to the 
 
inhibitory  effect of  the  NO  donor  SNP [21]. The  molecular  mechanism remains to be  
 
elucidated. Although  NO, by  elevating  intracellular  cGMP, is known  to inhibit  platelet  
 
activation [18], it has been recently demonstrated that the major NO synthase (NOS) isoform 
 
expressed in platelets, the endothelial NOS (eNOS), may play a stimulatory role in low dose  
 
agonist-induced platelet activation and promote an in vivo thrombotic response in an injury- 
 
induced arterial thrombosis  model [15,17]. Such stimulatory  role  of  eNOS  would be  
 
dependent on NO-mediated sGC activation and elevation of  cGMP, which in turn would 
 
promote the aggregation-dependent platelet secretion of granules contents [15,17]. Additional  
 
evidence  indicates that low concentrations of  NO promote  a  discrete platelet degranulation  
 
[23]. Given these  latest findings, the current concept of  NO  signalling  needs to be  revised 
 
highlighting the plausible biphasic role of NO in platelet activation; at the low concentrations,  
 
produced by platelet eNOS, NO would promote platelet secretion and aggregation, while at  
 
higher concentrations NO would inhibit platelet activation [15,17].  
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The present study aimes to investigate whether the NO/cGMP signalling pathway - upstream  
 
(Akt and eNOS phosphorylation) and downstream (VASP  phosphorylation) -  may  disclose  
 
abnormal patterns, in basal conditions and stimulated by SNP, in platelets from patients with 
 
an acute coronary syndrome (unstable angina and acute myocardial infarction). 
 
 
 
 
Materials and methods  
 
 
 
Study population  
 
The study population included 24 unrelated patients consecutively admitted at the Emergency  
 
Department with a diagnosis of acute coronary syndrome as a first manifestation of coronary  
 
artery disease. For inclusion the chest pain onset had to be within 8 hours from the admission.  
 
The  endorsed exclusion criteria  were  known history  of  coronary  heart  disease; previous  
 
coronary  revascularizations;  malignant hypertension; aortic  stenosis; hypertrophic  
 
cardiomyopathy; anemia; hypovolemia; chronic therapy with salicilates (or similars), statins 
 
or  other  antiplatelet and anticoagulant drugs; altered values of  circulating  platelets and  
 
coagulation factors; chronic inflammatory diseases; chronic steroid treatment (in the last 15 
 
days from admission); surgical procedures or major trauma within the last month.   
 
Ten patients presented with unstable angina and 14 with an acute myocardial infarction  
 
(defined  on the  Joint  European Society  of  Cardiology/American  Heart Association  
 
definitions) [26]. Eventually the control group included in the study constituted of 14 healthy  
 
subjects, macthed for  age  and sex  with the previous  groups and not presenting  clinical  
 
evidence  of coronary  heart disease. All subjects gave  written informed consent for  
 
participation in the study, which was approved by the institutional ethic committee and was  
 
performed according to the principles of the latest update of the Helsinki Declaration.  
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Platelets count, eritrosedimentation rate, fibrinogen and high sensitivity  C-reacting  protein  
 
were performed on blood samples collected with free-fall technique to avoid aggregation by  
 
local stasis, in one-tenth volume of 3.8% trisodium citrate and centrifuged for 10 minutes at 
 
3000 rpm. The venipuncture was performed in the Emergency Department before  any drug 
 
administration (aspirin,  nitrates or  anticoagulants). Measurements were  performed by  
 
conventional clinical chemistry methods.  
 
 
 
Measurement of serum soluble selectin-P and tumor necrosis factor-α  
 
Levels of  serum soluble selectin-P  (sP-selectin)  and tumor  necrosis factor-α  (TNF-α) were  
 
measured, respectively, with the human sP-selectin ELISA Kit (R&D Systems, Minneapolis, 
 
MN, USA)  and  the  human  TNFα  ELISA Kit  (Endogen, Pierce  Biotechnology, Rockford,  
 
USA).   
 
 
 
Materials  
 
Plasticware  was produced by  Falcon (Becton Dickinson, Franklin Lakes, NJ, USA). Tris 
 
buffer  saline  (TBS)  10X  was composed as  follows: 25 mM Tris base, 0.2 M glycine, 20% 
 
metanol, pH 8.5.  The  electrophoresis  reagents  were  produced  by  Bio-Rad Laboratories  
 
(Richmond, CA, USA). The protein contents of platelet-rich plasma (PRP) was assessed with 
 
the BCA kit  from Pierce  (Rockford, IL, USA).  Unless otherwise specified, reagents were  
 
purchased from Sigma Aldrich (Milano, Italy).  
 
 
 
Measurement of platelet cGMP  
 
The measurement of platelet cGMP was performed as previously described [4] in the absence  
 
or  presence  of SNP (12.5 μM), 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) (50 
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μM), 8-bromo guanosine-3',5'-cyclic  monophosphate  (8-Br-cGMP) (100 μM), 8-bromo 
 
guanosine-3',5'-cyclic  monophosphorothioate, and Rp-isomer (Rp-cGMPS; Calbiochem- 
 
Novabiochem Corporation, San Diego, CA, USA) (100 μM).  
 
 
 
Western blot analysis  
 
Aliquots of  PRP  from the  three  population groups were  pre-treated  for 15 minutes at 37°C  
 
with the NO donor SNP (12.5 μM), the sGC inhibitor ODQ (50 μM), a membrane-permeable  
 
analog of cGMP 8 Br-cGMP (100 μM), and the PKG inhibitor Rp-cGMPs (100 μM). Platelets  
 
were then sedimented by  centrifugation at 2000×g for 5 minutes and solubilized directly in  
 
lysis buffer (1% SDS, 0.1% Triton X-100, 10 mM Tris–HCl, 10% β-mercaptoethanol, 0.002%  
 
bromophenol blue, pH 7.4), supplemented with a protease inhibitor cocktail set III (100 mM 
 
4-(2-aminoethyl)benzenesulphonyl fluoride, 80 mM aprotinin, 5 mM bestatin, 1.5 mM E-64,  
 
2 mM leupeptin, 1 mM pepstatin; Calbiochem-Novabiochem Corporation,  San Diego, CA, 
 
USA). After centrifugation at 13,000×g for 15 minutes, aliquots containing 30 μg of proteins 
 
were  subjected to sodium  dodecylsulfate-polyacrylamide gel electrophoresis  (12%  
 
polyacrylamide),  transferred to  polyvinylidene  difluoride filter  membrane  (Immobilon 
P, 
 
Millipore, Bedford, MA, USA) and probed with the followings: a rabbit polyclonal antibody  
 
(diluted 1:100 in TBS  1X-  Non Fat Dry Milk 3% with 0.05%  Tween-20) specific for a  
 
chicken polyclonal antibody  anti-sGC α1β1  (1:500); a  sheep polyclonal antibody  anti- 
 
Akt1/PKBα  (0.5 μg/ml) (Upstate, D.B.A.; catalog no. 06-558) and a  sheep polyclonal  
 
antibody anti-phospho-Akt1/PKBα(Ser
473
) (0.5 μg/ml) (Upstate, D.B.A.; catalog no. 06-801);  
 
a  mouse  polyclonal antibody  anti-human eNOS  (0.25  μg/ml) (Transduction Laboratories,  
 
Lexington, KY; catalog no. 30030)  and a  rabbit  polyclonal anti-phospho-eNOS(Ser1177) 
 
antibody (0.5 μg/ml) (Cell Signaling, Celbio, Beverly, MA; catalog no. 9571), a vasodilator- 
 
stimulated phosphoprotein (anti-VASP) (0.2 μg/ml) (Cell  Signaling, Celbio, Beverly, MA; 
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catalog no. 3112); a mouse monoclonal antibody, clone 16C2, anti-VASP phosphorylated at 
 
serine  239 [anti-phospho-VASP(Ser
239
) (0.2 μg/ml) (Upstate, D.B.A., Lake  Placid, New  
 
York; catalog no. 05-611)].  
 
After  an overnight incubation, the membrane  was washed with PBS-Tween 0.1%  and  
 
subjected for  1 h to the following: peroxidase-conjugated antibody  (diluted 1:1000 in PBS- 
 
Tween with Blocker Non Fat Dry Milk 5%, Biorad Laboratories); anti-chicken γ-globulin 
 
(Calbiochem-Novabiochem Corporation; catalog  no. 345877); anti-sheep IgG (Upstate,  
 
D.B.A.; catalog no. 12-342); anti-mouse IgG or anti-rabbit (donkey; Amersham International;  
 
catalog no. NA931V and NA934V). The membrane was washed again with PBS-Tween, and  
 
proteins were visualized by the SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
 
Rockford, IL, USA). Molecular weight standards were used in all gels.  
 
 
 
 
Statistical analysis  
 
Continuous variables, presented as means and standard deviations  (SD), were  compared by  
 
Student’s t test for  equality  of  means after a  normalized distribution was assured  and by  
 
repeated-measures one-way  ANOVA followed  by  Bonferroni multiple comparison test. 
 
Categorical variables, presented as counts  and percentages, were  compared in cross  
 
tabulations tables by means of the Pearson chi-square test and likelihood ratio. All statistical  
 
analysis was performed with the program package STATA® v 8.0. The level of significance  
 
was taken as two-tailed p=0.05.  
 
 
 
Results  
 
Clinical and biochemical features of healthy subjects, UA and AMI patients are reported in 
 
Table 1. The platelets count (x 10
3
/mm
3
) in patients with UA (278±48) resulted significantly  
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lower compared to both patients with AMI (372±62, p<0.02) and healthy subjects (342±128,  
 
p<0.02).   
 
 
 
Serum markers of thrombophilic status and inflammation   
 
Serum markers of  platelet activation (sP-selectin), inflammation (TNF-α  and  
 
erythrosedimentation rate), thrombotic state  (fibrinogen) and plaque  disruption (HsCRP)  
 
proved higher in both UA and AMI patients compared to healthy controls (Table 1).  
 
Basal platelet cGMP (pmol/10
10
 platelets) was higher in both UA (1097±111, p<0.0001) and  
 
AMI patients (1122±77, p<0.0001) compared to healthy subjects (497±80) (Figure 1A).   
 
In SNP-treated platelets the absolute values of  cGMP  did not differ among  the three  study  
 
groups (Figure  1A), but when comparing  the difference  between SNP-stimulated and basal  
 
cGMP  levels in each group, the SNP stimulation in UA  patients proved  more  effective  (Δ  
 
3300±364 pmol/10
10
  platelets) than in healthy  subjects (Δ  1961±343 pmol/10
10
  platelets,  
 
p<0.01) and AMI patients (Δ 1296±153 pmol/10
10
 platelets, p<0.02) (Figure 1B). The SNP 
 
stimulation effect was instead not significantly  dissimilar  within AMI  patients and healthy  
 
controls (Figure 1B).  
 
Basal expression of  the sGC subunits  α1 and of  subunit β1 by  western blot  analysis  of  
 
platelets homogenates disclosed comparable patterns within the three study groups (Figure 2).  
 
 
 
 
Akt and eNOS phosphorylation   
 
Compared with platelets from healthy subjects, UA and AMI platelets showed a significant 
 
increase  in the activation of  the signalling  pathway  modulated by  NO, involving  the NOS  
 
activation by a cascade of protein kinases: the Akt1/PKBα phosphorylation at Ser
473
 (Figure  
 
3) and the eNOS phosphorylation at Ser1177 (Figure 4).  
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While  Phospho-VASP(Ser
239
), a  marker of  PKG  activation, was not detectable  in platelets  
 
from healthy  subjects, VASP  phosphorylation was clearly  present in UA  and even more  in  
 
AMI  platelets (Figure  5). SNP and 8-bromo-cGMP  incubation induced VASP  
 
phosphorylation in control and UA  platelets to  levels moreless superimposable to those 
 
basally  observed in AMI  platelets. Concerning  VASP  phosphorylation, AMI  platelets 
 
revealed unsensible  to SNP and 8-bromo-cGMP  incubation (Figure  5).  In healthy  and UA  
 
platelets ODQ reverted the SNP-induced effect, and Rp-8-Br-cGMPS reverted the 8-bromo- 
 
cGMP-induced effect, Suggesting, respectively, a  sGC and PKG  mediation. The  two 
 
inhibitors, instead, did  not decrease  phospho-VASP  levels in AMI  platelets, already  
 
maximally expressed under basal conditions (Figure 5).  
 
 
 
 
Discussion  
 
The  main finding  of the  present work  is that platelets from patients with acute  coronary  
 
syndromes not on therapy with salicilates (or derivatives), statins, or any other antiplatelet and  
 
anticoagulant drug, exhibit abnormal function. Furthermore patelets from patients presenting 
 
with UA or AMI disclosed different characteristics, both basal than SNP-induced.   
 
In comparison with healthy subjects, UA and AMI patients exhibited higher levels of serum 
 
sP-selectin (a sensitive marker of in vivo platelet activation [2]) and basal intraplatelet cGMP.  
 
Western blot analysis of the sGC isoforms expression excluded that this finding could have  
 
been attributable to a dissimilar isoform costitution compared to platelets from controls;  
 
indeed the basal expression of the sGC subunits α1 and of subunit β1 was comparable in the  
 
platelets from all the three study groups.  
 
Although the  30 year old dogma  that NO  and cGMP  play  inhibitory  roles in platelet 
 
activation, proven by the inhibited platelet function by high concentrations of NO donors and  
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cGMP  analogs [18], recent evidences suggested that, instead, low concentrations of  
 
endogenously  synthesized NO  and cGMP  may  promote  platelet secretion and aggregation  
 
[6,7,8]. The NO/cGMP pathway has therefore lately been entitled of a biphasic role in platelet 
 
activation.   
 
sGC activity, in several cell types, is modulated by NO, via a signalling pathway implicating 
 
the NOS activation by a cascade of protein kinases, such as PI3K and Akt/PKB [2]. PI3K has 
 
been observed to promote Akt activation during platelet stimulation [16,25], and two different  
 
isoforms of  Akt, Akt1/PKBα  and Akt2/PKBβ,  have  been found  to play  a  role  in platelet  
 
activation [3]. Once phosphorylated, Akt is known to phosphorylate and activate in its turn  
 
other proteins, including eNOS [9]. In fact, several platelet agonists may sequentially activate  
 
PI3K, Akt, and eNOS,  which synthesizes NO  [22]  and NO  stimulates sGC, causing  an  
 
increase of intracellular cGMP levels.   
 
In our experience this mechanism seemed apparently working in both UA and AMI platelets,  
 
as both the major downstream effector of PI3K (Akt) and the major downstream effector of  
 
Akt (eNOS) exhibited a  significant increase  in basal phosphorylation. The  product of  NOS  
 
activation, NO, may be responsible for the enhanced baseline concentrations of cGMP in both 
 
UA and AMI platelets, responsive to SNP in terms of cGMP production.   
 
Unfortunately  the evaluation of  the levels of  NO  produced by  platelets themselves is 
 
struggling, due to the impossibility to maintain these cells in culture for the incubation times 
 
(at least 12-24 hours)  generally  needed to measure  detectable  amounts of  nitrite, the stable  
 
derivative  of  NO. Furthermore, in an ex  vivo  study  like  the present, to administrate NOS  
 
inhibitors in vivo to patients and healthy controls checking the effect on basal platelet cGMP  
 
is not possible. Given these limitations the finding of higher Akt and eNOS phosphorylation, 
 
upstream steps of the NO/cGMP signalling pathway, seems highly relevant.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9  
  
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
Bergandi et al.: altered cGMP signalling in ACS  
The eNOS-generated NO, by stimulating sGC, may induce production of cGMP, which until  
 
recently  has been entitled to inhibit  platelet  activation by  activating  PKG. Recent  
 
experimental evidences, instead, have suggested that PKG may play an important stimulatory  
 
role in platelet activation. Mouse platelets knockout for PKG and human platelets treated with 
 
PKG  inhibitors showed significantly  reduced platelet aggregation in response to low dose  
 
agonists, including  thrombin, thromboxane  B2, von Willebrand factor  and collagen [15].  
 
VASP  (46-50 kDa) has been identified  as a  substrate for  both PKG  and  cAMP-dependent 
 
protein kinase (PKA). This phosphoprotein is preferentially phosphorylated at Ser
239
 by PKG  
 
and at Ser
157
  by  PKA  and the levels of  phospho-VASP(Ser
239
) have  been described as a  
 
reliable marker of  PKG  activation [14,19]. The  presented finding  of  a  significantly  
higher  
 
level of  phosphorylated VASP  in UA  and AMI  platelets compared to controls supports the 
 
hypothesis of an activated pathway, specifically downstream, in patients with acute coronary  
 
syndromes.  
 
Eventually  the  present work supports the evidence  that the cGMP  pathway  is,  in basal  
 
conditions, more  activated in platelets from acute coronary  syndrome  patients than in  
 
controls. One of the triggers of this phenomeon may be the proinflammatory cytokine TNF-α, 
 
as its circulating levels were significantly increased in both UA and AMI patients [8]. Indeed,  
 
TNF-α is known to promote platelet aggregation in patients with heart failure [20], and has 
 
been recently shown to stimulate eNOS phosphorylation via the PI3K/Akt signal transduction  
 
pathway [13,1,7].  
 
Previous literature has reported that acute coronary syndormes relate with NO resistance, as  
 
decreased platelet responsiveness to the antiaggregatory  effects of  NO  donors [4].  
 
Interestingly, our investigation showed that the  ability  of the NO  donor  SNP to further  
 
increase  cGMP  was fully  maintained in platelets from UA  patients, while it  was strongly  
 
impaired in AMI platelets, suggesting dissimilar platelet reactions in these two groups. The  
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resistance of AMI platelets was exhibited not only at the sGC step, but also at the PKG step:  
 
both SNP and 8-Br-cGMP  were  unable  to increase  VASP  phosphorylation levels. Such  
 
finding  could be  consequence  of  the already  high and stable  basal level of  VASP  
 
phosphorylation in AMI platelets not revertable either by the sGC inhibitor ODQ or the PKG  
 
inhibitor Rp-8-Br-cGMPS.  
 
 
 
Conclusion  
 
The  onset of  NO  resistance  observed in patients with acute coronary  syndromes has been  
 
mainly attributed to a not yet clearly defined impairment of sGC and/or to the scavenging of  
 
NO  by  the  superoxide anion radical [10], however  the precise  molecular  modifications  
 
responsible for the desensitisation of the NO/cGMP pathway has hitherto not been identified.  
 
The present data suggest that NO resistance in this setting of patients may involve other steps 
 
than the sGC alone: in UA  and AMI  patients the alteration of  the  cGMP  pathway  is more  
 
complex  than the  previously  hypothesized, showing  quantitative differences among  the 
two 
 
groups of patients. It is conceivable that the increased phosphorylation of VASP in UA and  
 
AMI  platelets is a  relatively  stable  modification, caused by  a  prolonged NO-mediated 
 
stimulation of the cGMP pathway and no longer sensitive to sGC and PKG inhibitors.   
 
Platelet hyperaggregability  combined with hyporesponsiveness to exogenous NO  donors in  
 
AMI patients may reflect an impaired physiological response to endogenous NO, and could 
 
contribute  to the increased risk of  ischemic  events. Moreover, nitrate therapy  may  be  
least 
 
likely to obtain beneficial results [6]. Indeed Willoughby et al. showed that a reduced platelet  
 
response to NO administration in the first hours from the onset of symptoms was associated 
 
with a worse prognosis in UA patients, as to relapsed incidence and increased mortality [28]. 
 
In fact, in AMI  patients, there  is lack of  evidence  supporting  nitrovasodilators efficacy  in  
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inhibiting platelet activation, and these drugs have not proved beneficial in terms of mortality  
 
reduction [5].  
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Table 1. Clinical and biochemical features of healthy subjects, unstable angina and acute  
 
myocardial infarction patients.   
 
 
Variable  healthy subjects  UA patients  AMI patients  
 
(n=14)  (n=10)  (n=14)  
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
Age  
 
Sex, % male  
 
Platelets count  
 
(x 10
3
/mm
3
)  
 
ESR (mm/h)  
 
Fibrinogen (mg/dl)  
 
HsCRP (mg/dl)  
 
sP-selectin (ng/ml)  
 
TNF-α (pg/ml)  
 
Diabetes  
 
Hypertension  
 
Familiarity  
 
Dyslipidemia  
64.3 ± 0.98  
 
57% (8/14)  
 
342 ± 128  
 
 
 
1.5 ± 0.4  
 
210.6 ± 6.5  
 
2.6 ± 0.24  
 
82 ± 19  
 
7.8 ± 1.4  
 
4/14 (30%)  
 
8/14 (60%)  
 
2/14 (10%)  
 
5/14 (35%)  
66 ± 1.29  
 
40% (4/10)  
 
278 ± 48 * °  
 
 
 
16.9 ± 1.6 **  
 
610.1 ± 32.6 ***  
 
15.2 ± 0.71 ***  
 
107 ± 21 *  
 
19.2 ± 3.2 *  
 
6/10 (60%)  
 
8/10 (80%)  
 
2/10 (20%)  
 
6/10 (60%)  
68.5 ± 1.29  
 
64% (9/14)  
 
372 ± 62  
 
 
 
12.7 ± 1.6 **  
 
673.3 ± 54.6 ***  
 
17.5 ± 1.13 ***  
 
123 ± 22 **  
 
22.4 ± 3.8 *  
 
11/14 (78%)  
 
13/14 (93%)  
 
2/14 (14%)  
 
12/14 (85%)  
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
UA, unstable angina; AMI, acute myocardial infarction; ESR = erythrosedimentation rate, 
 
HsCRP = Hight sensibility C-reactive protein, TNF-α = tumor necrosis factor-α  
 
* p < 0.02, ** p < 0.01, *** p < 0.0001 vs. healthy subjects  
 
° p < 0.02 vs. patients with AMI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17  
  
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
Bergandi et al.: altered cGMP signalling in ACS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18  
  
 
 
 1 
 2 
 3 
 4 
 
 
 
 
 
 
Figure 1.   
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A. Basal and SNP-dependent cGMP synthesis in platelets of healthy (CTRL) subjects (n=14),  
in UA patients (n=10) and in AMI patients (n=14). Platelets were incubated for 15 minutes at 
 
37° C  in the  absence  (basal)  or  presence  of  12.5 M SNP. cGMP  concentration was  
 
determined as described under Materials and Methods. Data are presented as mean ± SD. *  p 
 
< 0.0001 vs. respective basal; p < 0.0001 vs. basal of healthy control patients.  
 
B. Elaboration of  data presented in panel A,  showing  the  SNP-dependent cGMP  increase  
 
from basal  level in platelets from healthy  (CTRL)  subjects, UA patients  and AMI  patients.  
 
Data are presented as mean ± SD. * p < 0.01 vs. healthy control patients; p< 0.02 vs. SNP- 
 
dependent cGMP increase in AMI patients.  
 
 
 
 
Figure 2.   
 
Expression of sGC subunits α1 (73-82 kDa) and β1 (70-72 kDa) in healthy subjects (CTRL),  
 
in UA patients and AMI patients. Western blot analysis was performed as described under the  
 
Materials and Methods section.  
 
Top.  The  figure  is representative of  the experiments performed on each healthy  subject or  
 
patient.  
 
Bottom. The protein bands obtained from 14 healthy subjects (CTRL), 10 UA patients and 14 
 
AMI  patients have  been  quantitated densitometrically. Values, expressed  as arbitrary  
units, 
 
are represented as means ± SD.  
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Top.  Expression of  Akt1/PKBα  and phosphorylation of  Akt1/PKBα  at  Ser
473
  in healthy  
 
subjects (CTRL), in UA patients (UA) and AMI patients (AMI). Western blot analysis was  
 
performed as described under the Materials and Methods section. The figure is representative  
 
of the experiments performed on each healthy subject or patient.  
 
Bottom. The protein bands obtained from 14 healthy subjects (CTRL), 10 UA patients and 14 
 
AMI  patients have  been  quantitated densitometrically. Values, expressed  as arbitrary  
units, 
 
are represented as means ± SD; * p < 0.02 and ** p < 0.01 vs. healthy subjects; ° p < 0.02 vs.  
 
UA patients.  
 
 
 
Figure 4.   
 
Top  -  Expression of  eNOS  and phosphorylation of  eNOS  at Ser1177  in healthy  subjects  
 
(CTRL), in UA patients (UA) and AMI patients (AMI). Western blot analysis was performed  
 
as described under the Materials and Methods section. The  figure  is representative of  the  
 
experiments performed on each healthy subject or patient.  
 
Bottom  - The protein bands obtained from 14 healthy subjects (CTRL), 10 UA patients and  
 
14 AMI patients have been quantitated densitometrically. Values, expressed as arbitrary units, 
 
are represented as means ± SD; *p < 0.001 and ** p < 0.0001 vs. healthy subjects; ° p < 0.01  
 
vs. UA patients. 
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Figure 5.   
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Top. VASP phosphorylation at Ser
239
 in healthy subjects (panel A), in UA patients (panel B)  
 
and AMI patients (panel C). PRP was incubated for 15 minutes at 37° C with 12.5M SNP 
 
(snp)  and 500 M 8-Br-cGMP  (br) alone or  in presence, respectively, of  50 M ODQ  
 
(snp+odq), a guanylate cyclase inhibitor, and of 500 M Rp-8-Br-cGMPS (br+rp), a selective  
 
inhibitor of PKG. ODQ and Rp-8-Br-cGMPS alone gave results superimposable to ctrl (data  
 
not shown). The figure is representative of the experiments performed on each healthy subject  
 
or patient. Western blot analysis was performed as described under the Materials and Methods  
 
section.   
 
Bottom. The protein bands obtained in three experiments from 14 healthy subjects (CTRL),  
 
10 UA  patients and 14 AMI  patients have  been  quantitated densitometrically. VASP  Ser
239
 
 
was analyzed by immunoblotting using  an anti-phospho-VASP antibody  (16C2) against the  
 
Ser
239
  of  phosphorylated  VASP. Values,  expressed as  arbitrary  units, are  means ±  SEM 
of  
 
three separate experiments. * p < 0.01 and ** p < 0.001 vs.ctrl; ° p < 0.02 vs. snp and °° p <  
 
0.002; ◊ p < 0.01 and ◊◊ p < 0.001 vs. br 
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